BioCina Pty Ltd. and NovaCina Pty Ltd. have formed a strategic alliance to provide integrated biologics solutions. BioCina will leverage NovaCina’s fill-and-finish expertise to deliver high-quality drug products. This collaboration represents a milestone in offering end-to-end biopharmaceutical manufacturing solutions, promising unparalleled quality and adherence to regulatory standards, benefiting clients globally.
Adelaide, South Australia, and Perth, Western Australia, February 27, 2024 /PRNewswire/ — BioCina Pty Ltd., a leading global biologics Contract Development and Manufacturing Organization (CDMO), and NovaCina Pty Ltd., a prominent fill-and-finish CDMO, have announced a strategic alliance aimed at delivering integrated solutions for biologics developers. This collaboration empowers BioCina to furnish top-tier fill-and-finish services to its clientele by leveraging NovaCina’s expertise. It involves the conversion of drug substances produced at BioCina’s cutting-edge facility in Adelaide, South Australia, into ready-to-use drug products at NovaCina’s advanced facility in Perth, Australia. The partnership marks a significant advancement in offering comprehensive biopharmaceutical manufacturing solutions to clients worldwide.
“Our partnership pledges unparalleled quality and adherence to the most stringent regulatory standards, thereby establishing new industry benchmarks,” stated Mark W. Womack, Chief Executive Officer of BioCina and a member of NovaCina’s Board of Directors.
BioCina specializes in providing premium CDMO services, including cell line development, process development, and cGMP drug substance manufacturing for microbial, pDNA, and mRNA modalities.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Through this alliance, BioCina’s clients gain access to NovaCina’s extensive experience in clinical and commercial fill-and-finish operations, bolstered by multiple regulatory approvals, including from the U.S. Food and Drug Administration (FDA). NovaCina offers a comprehensive array of services spanning development, manufacturing, packaging, labeling, and stability studies.
“We are thrilled to partner with NovaCina, seamlessly integrating our globally acclaimed expertise in clinical and commercial process development and drug substance manufacturing with their distinguished drug product services,” commented Mark W. Womack, BioCina’s CEO.
Cyrus K. Mirsaidi, CEO of NovaCina, expressed enthusiasm about the collaboration, stating, “We are delighted to join forces with BioCina to provide a seamless end-to-end solution. At NovaCina, we are committed to bringing our world-class quality and safety standards to this mutually beneficial partnership.”